Immune Complex Membranoproliferative Glomerulonephritis Market Expected to Experience Robust Growth and Market Evolution by 2036 - DelveInsight

DelveInsight's "Immune Complex Membranoproliferative Glomerulonephritis - Market Insights, Epidemiology and Market Forecast - 2036" report offers an in-depth understanding of IC-MPGN, historical and forecasted epidemiology, as well as the IC-MPGN market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Get more details on the IC-MPGN Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Immune Complex Membranoproliferative Glomerulonephritis Market Report

• In March 2026, Biogen and Apellis Pharmaceuticals announced that the companies had entered into a definitive agreement under which Biogen agreed to acquire Apellis.
• In February 2026, SanegeneBio announced that SGB-9768 received Orphan Drug Designation from the US FDA for the treatment of IC-MPGN.
• The Immune Complex Membranoproliferative Glomerulonephritis market size was found to be ~USD 30 million in the leading markets (the United States, EU4, the United Kingdom, and Japan) in 2025, and is expected to grow at a CAGR of 26% during the forecast period 2026-2036.
• According to a UK registry, the minimal point prevalence is 1.3 per 100,000 for MPGN UK-wide.
• In 2025, the total number of diagnosed prevalent cases of IC-MPGN in the 7MM was about 7,000, with the US accounting for the highest number at ~3,500 cases, followed by Japan.
• In 2025, there was a significant disparity in IC-MPGN cases between children and adults in the US: children accounted for only about 10% of total cases, while adults accounted for approximately 3,400 cases.
• Males represent more than 50% of the total IC-MPGN cases in the US in 2025, and the disease is more prevalent in adults than in pediatrics.
• The estimated global annual incidence of C3G ranges from 1 to 3 cases per million individuals, and up to 30-35% of patients with C3G or idiopathic IC-MPGN develop kidney failure within 10 years of diagnosis.
• Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis therapy.
• In the VALIANT study, EMPAVELI demonstrated a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits compared to placebo; EMPAVELI is supported by a strong safety profile with over 3,000 patient-years of systemic pegcetacoplan exposure.
• Iptacopan (LNP023), an oral, first-in-class complement factor B inhibitor from Novartis, is currently in a Phase III (APPARENT) study for idiopathic IC-MPGN, with clinical trial data readout anticipated in 2028 according to the company's February 2026 investor presentation.
• Among the 7MM, the US accounted for the largest IC-MPGN market size at approximately USD 20 million in 2025.
• Key Immune Complex Membranoproliferative Glomerulonephritis Companies: Biogen (Apellis Pharmaceuticals), Swedish Orphan Biovitrum AB, SanegeneBio, Novartis.
• Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: Pegcetacoplan (EMPAVELI) - recently approved, Iptacopan (LNP023), SGB-9768.
• The Immune Complex Membranoproliferative Glomerulonephritis market is expected to grow steadily from 2022-2036, driven by the launch of approved therapies, rising disease awareness, and the entry of late- to mid-stage pipeline candidates.

Immune Complex Membranoproliferative Glomerulonephritis Overview

Primary IC-MPGN is a rare, chronic kidney disorder in which excessive C3 deposits are a key marker of disease activity, leading to kidney inflammation, damage, and failure. IC-MPGN can be primary (idiopathic) or secondary to underlying conditions such as infections, autoimmune diseases, or malignancies, and is classified as idiopathic only after an exhaustive evaluation fails to identify an underlying cause. Emerging evidence suggests that a subset of idiopathic cases may be driven by dysregulation and overactivation of the alternative complement pathway. Clinically, patients often present with proteinuria, hematuria, hypertension, and declining kidney function, and the disease may progressively lead to chronic kidney disease (CKD) or end-stage kidney failure if not adequately managed.

To know in detail about the IC-MPGN market outlook, drug uptake, treatment scenario, and epidemiology trends, click here:
https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation

• Total Prevalent Cases of IC-MPGN
• Total Diagnosed Prevalent Cases of IC-MPGN
• Gender-specific Incident Cases of IC-MPGN
• Age-specific Incident Cases of IC-MPGN

Immune Complex Membranoproliferative Glomerulonephritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the IC-MPGN market or expected to launch during the study period. The uptake of therapies is expected to be based on clinical positioning, mechanism of action, and stage of development. The recently introduced complement-targeted therapy pegcetacoplan is projected to see moderate uptake, driven by its mechanism-based approach targeting central complement activation and the high unmet need in complement-mediated renal diseases. Pipeline agent iptacopan is expected to follow a gradual to moderate uptake trajectory, reflecting its investigational status, with its oral administration and targeted inhibition of the alternative pathway potentially supporting broader adoption over time.

The report also covers the IC-MPGN Pipeline Development Activities, providing insights into different therapeutic candidates across Phase II-III clinical trials and the key companies involved in developing targeted therapeutics, along with collaborations, patents, and other developments.

Immune Complex Membranoproliferative Glomerulonephritis Therapies and Key Companies

• Pegcetacoplan (EMPAVELI): Biogen (Apellis Pharmaceuticals) and Swedish Orphan Biovitrum AB
• Iptacopan (LNP023): Novartis
• SGB-9768: SanegeneBio

Discover more about therapies set to grab major IC-MPGN market share:
https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Immune Complex Membranoproliferative Glomerulonephritis Market Drivers

• Rising prevalence and underlying conditions: increasing prevalence is driven by long-term infections such as hepatitis C, autoimmune diseases such as lupus nephritis, and monoclonal gammopathy (often in adults), which drive the need for treatment.
• Lack of approved therapies: the absence of specific, FDA-approved drugs has meant the market was historically dominated by off-label treatments, including immunosuppressants, steroids, and RAAS inhibitors, driving organizations to develop new, targeted therapies.
• Improved diagnostics: better diagnostic technologies and increased awareness among clinicians for distinguishing IC-MPGN from C3 Glomerulopathy (C3G) are leading to earlier, more frequent diagnoses, boosting treated patient numbers.

Immune Complex Membranoproliferative Glomerulonephritis Market Barriers

• Limited approved therapies, with treatment historically relying on supportive care and broad immunosuppression using renin-angiotensin system blockers, diuretics, corticosteroids, and other immunosuppressive agents.
• Diagnostic challenges, including difficulty distinguishing IC-MPGN from underlying causes and from closely related entities such as C3G, along with diagnostic delays that can hinder timely treatment.
• High risk of progression to kidney failure, with a substantial proportion of patients with C3G or idiopathic IC-MPGN developing kidney failure within 10 years of diagnosis despite available supportive management.

Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report

• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM
• Key IC-MPGN Companies: Biogen (Apellis Pharmaceuticals), Swedish Orphan Biovitrum AB, SanegeneBio, Novartis
• Key IC-MPGN Therapies: Pegcetacoplan (EMPAVELI), Iptacopan (LNP023), SGB-9768
• IC-MPGN Therapeutic Assessment: Current marketed and emerging therapies
• IC-MPGN Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis
• IC-MPGN Unmet Needs, KOL's Views, Analyst's Views, Market Access and Reimbursement

Table of Contents

• Immune Complex Membranoproliferative Glomerulonephritis Market Key Insights
• Immune Complex Membranoproliferative Glomerulonephritis Market Report Introduction
• Immune Complex Membranoproliferative Glomerulonephritis Market Executive Summary
• Immune Complex Membranoproliferative Glomerulonephritis Market Key Events
• Immune Complex Membranoproliferative Glomerulonephritis Epidemiology and Market Forecast Methodology
• Immune Complex Membranoproliferative Glomerulonephritis Market Overview
• Immune Complex Membranoproliferative Glomerulonephritis Disease Background and Overview
• Immune Complex Membranoproliferative Glomerulonephritis Epidemiology and Patient Population
• Immune Complex Membranoproliferative Glomerulonephritis Patient Journey
• Immune Complex Membranoproliferative Glomerulonephritis Marketed Therapies
• Immune Complex Membranoproliferative Glomerulonephritis Emerging Therapies
• Immune Complex Membranoproliferative Glomerulonephritis Market Analysis (7MM)
• Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs
• Immune Complex Membranoproliferative Glomerulonephritis SWOT Analysis
• Immune Complex Membranoproliferative Glomerulonephritis Key Opinion Leaders (KOL) Views
• Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.